Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses

M. Rovaris, M. Codella, L. Moiola, A. Ghezzi, M. Zaffaroni, G. Mancardi, E. Capello, F. Sardanelli, G. Comi, M. Filippi

Research output: Contribution to journalArticle

Abstract

This baseline-vs-treatment study of 20 patients with relapsing-remitting MS investigated whether glatiramer acetate (GA) has a graduated effect on MS inflammatory activity, which was measured using monthly, standard, and triple dose gadolinium (Gd)-enhanced MRI. GA significantly reduced the mean numbers of enhancing lesions/patient/month on both standard dose and triple dose scans, without interactions with the Gd dose. GA is effective in reducing MS activity, independent of the severity of the MRI-detectable inflammatory process.

Original languageEnglish
Pages (from-to)1429-1432
Number of pages4
JournalNeurology
Volume59
Issue number9
Publication statusPublished - Nov 12 2002

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses'. Together they form a unique fingerprint.

  • Cite this